Literature DB >> 9810000

Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia.

O E Bechter1, W Eisterer, G Pall, W Hilbe, T Kühr, J Thaler.   

Abstract

The telomere-telomerase hypothesis states that the vast majority of human tumors have a prolonged replicative life span throughout expressing telomerase, which compensates the cell division-associated loss of telomere DNA. The use of telomere length and telomerase expression as new biological markers in cancer patients requires their correlation with disease prognosis. We, therefore, correlated the mean telomere length based on a telomere restriction fragment assay and the activity of telomerase measured with a telomeric repeat amplification protocol with clinical data and overall survival in 58 patients with B cell chronic lymphocytic leukemia (B-CLL). Telomere length showed a highly inverse correlation to telomerase activity. Patients with telomeres below 6.0 kb were associated with high telomerase activity, whereas patients with a telomere length >6.0 kb generally showed low enzyme activity (P <0.001). Patients in Binet A exhibited significantly longer telomeres and had less telomerase activity than did patients in Binet B or Binet C, where significantly shorter telomeres and higher telomerase activity were observed (P=0.031). Short telomere length and high telomerase activity were significantly associated with a shorter median survival (P=0.02 and P <0.001), and telomerase activity was the most significant prognostic factor for overall survival in B-CLL (P <0.001). Our data provide evidence that telomere length, as well telomerase activity, exerts a strong impact on the survival of B-CLL patients and that telomerase activity can be used as a new prognostic marker in this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9810000

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

Review 1.  Complex regulation of telomerase activity: implications for cancer therapy.

Authors:  K S Elenitoba-Johnson
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

2.  Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.

Authors:  Masood A Shammas; Aamer Qazi; Ramesh B Batchu; Robert C Bertheau; Jason Y Y Wong; Manjula Y Rao; Madhu Prasad; Diptiman Chanda; Selvarangan Ponnazhagan; Kenneth C Anderson; Christopher P Steffes; Nikhil C Munshi; Immaculata De Vivo; David G Beer; Sergei Gryaznov; Donald W Weaver; Raj K Goyal
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

3.  T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.

Authors:  Rajendra N Damle; Sonal Temburni; Taraneh Banapour; Santanu Paul; Patricia K A Mongini; Steven L Allen; Jonathan E Kolitz; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2012-08-08       Impact factor: 22.113

4.  Telomeres and prognosis in patients with chronic lymphocytic leukaemia.

Authors:  Ludger Sellmann; Dirk de Beer; Marius Bartels; Bertram Opalka; Holger Nückel; Ulrich Dührsen; Jan Dürig; Marc Seifert; Dörte Siemer; Ralf Küppers; Gabriela M Baerlocher; Alexander Röth
Journal:  Int J Hematol       Date:  2011-01-05       Impact factor: 2.490

5.  Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.

Authors:  Billy Michael Chelliah Jebaraj; Eugen Tausch; Dan A Landau; Jasmin Bahlo; Sandra Robrecht; Amaro N Taylor-Weiner; Johannes Bloehdorn; Annika Scheffold; Daniel Mertens; Sebastian Böttcher; Michael Kneba; Ulrich Jäger; Thorsten Zenz; Michael K Wenger; Guenter Fingerle-Rowson; Clemens Wendtner; Anna-Maria Fink; Catherine J Wu; Barbara Eichhorst; Kirsten Fischer; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Leukemia       Date:  2019-03-25       Impact factor: 11.528

6.  The evaluation of hTERT mRNA expression in acute leukemia children and 2 years follow-up of 40 cases.

Authors:  Ozgur Cogulu; Buket Kosova; Cumhur Gunduz; Emin Karaca; Serap Aksoylar; Ayse Erbay; Deniz Karapinar; Canan Vergin; Filiz Vural; Murat Tombuloglu; Nazan Cetingul; Ferda Ozkinay
Journal:  Int J Hematol       Date:  2008-02-22       Impact factor: 2.490

Review 7.  Association between telomere length and survival in cancer patients: a meta-analysis and review of literature.

Authors:  Xinsen Xu; Kai Qu; Qing Pang; Zhixin Wang; Yanyan Zhou; Chang Liu
Journal:  Front Med       Date:  2016-05-16       Impact factor: 4.592

8.  Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.

Authors:  M A Shammas; H Koley; R C Bertheau; P Neri; M Fulciniti; P Tassone; S Blotta; A Protopopov; C Mitsiades; R B Batchu; K C Anderson; A Chin; S Gryaznov; N C Munshi
Journal:  Leukemia       Date:  2008-05-01       Impact factor: 11.528

9.  Impact of telomere length on survival in classic and variant hairy cell leukemia.

Authors:  Evgeny Arons; Hong Zhou; Daniel C Edelman; Allison Gomez; Seth M Steinberg; David Petersen; Yonghong Wang; Paul S Meltzer; Robert J Kreitman
Journal:  Leuk Res       Date:  2015-09-24       Impact factor: 3.156

Review 10.  Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

Authors:  Michele Dal-Bo; Francesco Bertoni; Francesco Forconi; Antonella Zucchetto; Riccardo Bomben; Roberto Marasca; Silvia Deaglio; Luca Laurenti; Dimitar G Efremov; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2009-08-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.